A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-02

AUTHORS

Elisabeth I. Heath, Keith Bible, Robert E. Martell, Daniel C. Adelman, Patricia M. LoRusso

ABSTRACT

PURPOSE: SNS-032, (formerly BMS-387032) is a potent and selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9. The primary objective of the study was to establish the maximum tolerated dose (MTD), the maximum administered dose (MAD), dose limiting toxicity (DLT), and the recommended phase 2 dose for SNS-032 when administered as a weekly 1-h infusion. The secondary objective was to assess the safety and tolerability of SNS-032 and to evaluate its bioavailability as an oral solution. METHODS: Patients with metastatic solid tumors or refractory lymphoma were treated with a starting dose of 4 mg/m2 intravenously administered over 1-h with a cycle defined as 3 weekly doses of SNS-032 every 21 days. Three patient cohorts were utilized in the dose-escalation schema. Pharmacokinetic studies were performed. For the 13 and 16 mg/m2 dose cohorts, the first dose of cycle 2 was given as an oral solution to estimate the oral bioavailability of the drug in humans. RESULTS: A total of 21 patients were enrolled. Twenty treated patients received a total of 39 cycles of treatment. The most common treatment-related adverse events occurring with greater than 20% incidence were fatigue (25%) and nausea (20%). Following intravenous administration, plasma concentrations declined in a biphasic manner, resulting in mean terminal half-lives between 5 and 10 hours. The mean Cmax and AUC0-inf increased nearly linearly with dose, ranging from 0.067 to 0.287 microg/ml and 0.103 to 0.553 microg h/ml, respectively. The CL and Vss remained unchanged with increasing dose levels, averaging 38 l/h/m2 and 212 l/m2, respectively. Average oral bioavailability was 19% (range: 4-33%). Three (15%) patients experienced a best response of stable disease. Study enrollment was terminated during dose-escalation due to a change in the development strategy for the study drug. CONCLUSIONS: SNS-032 administered as a weekly 1-h infusion was well tolerated, although study enrollment was terminated during dose-escalation and the MTD of SNS-032 administered intravenously on days 1, 8, and 15 of each treatment cycle was not reached. Tumor progression or stable disease was determined to be the best response in all evaluable patients. At the dose levels tested, the oral bioavailability of SNS-032 ranged from 4-33%. The data suggest that oral administration of SNS-032 may be feasible, though the tolerability and bioavailability of the oral formulation would have to be formally assessed. More... »

PAGES

59-65

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-007-9090-3

DOI

http://dx.doi.org/10.1007/s10637-007-9090-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1044972352

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17938863


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Availability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CDC2-CDC28 Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Half-Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wayne State University", 
          "id": "https://www.grid.ac/institutes/grid.254444.7", 
          "name": [
            "Wayne State University/Karmanos Cancer Institute, 4100 John R, 4HWCRC, 48201, Detroit, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heath", 
        "givenName": "Elisabeth I.", 
        "id": "sg:person.01136603555.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136603555.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mayo Clinic", 
          "id": "https://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Mayo Clinic, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bible", 
        "givenName": "Keith", 
        "id": "sg:person.0774753133.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774753133.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Methylgene, Montreal, Quebec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martell", 
        "givenName": "Robert E.", 
        "id": "sg:person.01074762666.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074762666.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sunesis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.422684.e", 
          "name": [
            "Sunesis Pharmaceuticals, Inc., San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adelman", 
        "givenName": "Daniel C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wayne State University", 
          "id": "https://www.grid.ac/institutes/grid.254444.7", 
          "name": [
            "Wayne State University/Karmanos Cancer Institute, 4100 John R, 4HWCRC, 48201, Detroit, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "LoRusso", 
        "givenName": "Patricia M.", 
        "id": "sg:person.012616064757.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012616064757.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/b:drug.0000026258.02846.1c", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012390955", 
          "https://doi.org/10.1023/b:drug.0000026258.02846.1c"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semcancer.2005.04.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032104046"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semcancer.2005.04.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032104046"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9440(10)65593-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036900656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-03-0050", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037461456"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ygyno.2005.05.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046291497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ygyno.2005.05.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046291497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2741/1871", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070914153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074769896", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-02", 
    "datePublishedReg": "2008-02-01", 
    "description": "PURPOSE: SNS-032, (formerly BMS-387032) is a potent and selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9. The primary objective of the study was to establish the maximum tolerated dose (MTD), the maximum administered dose (MAD), dose limiting toxicity (DLT), and the recommended phase 2 dose for SNS-032 when administered as a weekly 1-h infusion. The secondary objective was to assess the safety and tolerability of SNS-032 and to evaluate its bioavailability as an oral solution.\nMETHODS: Patients with metastatic solid tumors or refractory lymphoma were treated with a starting dose of 4 mg/m2 intravenously administered over 1-h with a cycle defined as 3 weekly doses of SNS-032 every 21 days. Three patient cohorts were utilized in the dose-escalation schema. Pharmacokinetic studies were performed. For the 13 and 16 mg/m2 dose cohorts, the first dose of cycle 2 was given as an oral solution to estimate the oral bioavailability of the drug in humans.\nRESULTS: A total of 21 patients were enrolled. Twenty treated patients received a total of 39 cycles of treatment. The most common treatment-related adverse events occurring with greater than 20% incidence were fatigue (25%) and nausea (20%). Following intravenous administration, plasma concentrations declined in a biphasic manner, resulting in mean terminal half-lives between 5 and 10 hours. The mean Cmax and AUC0-inf increased nearly linearly with dose, ranging from 0.067 to 0.287 microg/ml and 0.103 to 0.553 microg h/ml, respectively. The CL and Vss remained unchanged with increasing dose levels, averaging 38 l/h/m2 and 212 l/m2, respectively. Average oral bioavailability was 19% (range: 4-33%). Three (15%) patients experienced a best response of stable disease. Study enrollment was terminated during dose-escalation due to a change in the development strategy for the study drug.\nCONCLUSIONS: SNS-032 administered as a weekly 1-h infusion was well tolerated, although study enrollment was terminated during dose-escalation and the MTD of SNS-032 administered intravenously on days 1, 8, and 15 of each treatment cycle was not reached. Tumor progression or stable disease was determined to be the best response in all evaluable patients. At the dose levels tested, the oral bioavailability of SNS-032 ranged from 4-33%. The data suggest that oral administration of SNS-032 may be feasible, though the tolerability and bioavailability of the oral formulation would have to be formally assessed.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-007-9090-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "26"
      }
    ], 
    "name": "A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors", 
    "pagination": "59-65", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-007-9090-3"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d637d843eccfb41457e43f3ed20db3cf1787635efd177aec3da212ece461fcba"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1044972352"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17938863"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-007-9090-3", 
      "https://app.dimensions.ai/details/publication/pub.1044972352"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000376_0000000376/records_56185_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-007-9090-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-007-9090-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-007-9090-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-007-9090-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-007-9090-3'


 

This table displays all metadata directly associated to this object as RDF triples.

220 TRIPLES      21 PREDICATES      60 URIs      44 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-007-9090-3 schema:about N02bad94f4fe7491b906d022c5d69a278
2 N0ea725702b8c4ac3868d138236bf48a9
3 N0ec2807d1f334ade92632765f21ac32c
4 N1b95010bb44a4a71b8c0645778a143cc
5 N1c70daddf2d842cca11c6508c13fc8a3
6 N2f89d00122b14f509086141c2d577082
7 N3351f268906d4ad2aa73b9f0e0515405
8 N3d71d4b901194899881bb02d95b2c842
9 N419874bf8218447aab5a0cec4f3c08af
10 N49b3e507bc804c2faf5e22715f5adaea
11 N57b760e501754084b3c7a095bb9bddfd
12 N5f3c9ea2d0344f1f94b33678795d8cec
13 N74b3e57b51464276b65d92d66f17a45c
14 N90810ff547df41fb88c596b770f648e2
15 N92d53c7ab5b746978e36cfb37777136d
16 Nb06223a438e2448fbb764e855c5e9863
17 Nb3da32ccb88443dd8561b02ef2100f4a
18 Nd3c16dc0b36147ae858536c04d9cbf34
19 Ne03f090571564f28bc5b4c1f55edb85f
20 Ne9e73d17ced04cabb35fed464c3ee922
21 Nf04d338c07994a7aa64a5091a3989395
22 Nf8f7fb383042459f90d837515491c191
23 Nfa903ddde57b4203b2198d1abaf95cbd
24 anzsrc-for:11
25 anzsrc-for:1115
26 schema:author N4e893f104b6f460ba9a9dbc3ecbd2c43
27 schema:citation sg:pub.10.1023/b:drug.0000026258.02846.1c
28 https://app.dimensions.ai/details/publication/pub.1074769896
29 https://doi.org/10.1016/j.semcancer.2005.04.007
30 https://doi.org/10.1016/j.ygyno.2005.05.017
31 https://doi.org/10.1016/s0002-9440(10)65593-9
32 https://doi.org/10.1093/jnci/92.3.205
33 https://doi.org/10.1158/1078-0432.ccr-03-0050
34 https://doi.org/10.2741/1871
35 schema:datePublished 2008-02
36 schema:datePublishedReg 2008-02-01
37 schema:description PURPOSE: SNS-032, (formerly BMS-387032) is a potent and selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9. The primary objective of the study was to establish the maximum tolerated dose (MTD), the maximum administered dose (MAD), dose limiting toxicity (DLT), and the recommended phase 2 dose for SNS-032 when administered as a weekly 1-h infusion. The secondary objective was to assess the safety and tolerability of SNS-032 and to evaluate its bioavailability as an oral solution. METHODS: Patients with metastatic solid tumors or refractory lymphoma were treated with a starting dose of 4 mg/m2 intravenously administered over 1-h with a cycle defined as 3 weekly doses of SNS-032 every 21 days. Three patient cohorts were utilized in the dose-escalation schema. Pharmacokinetic studies were performed. For the 13 and 16 mg/m2 dose cohorts, the first dose of cycle 2 was given as an oral solution to estimate the oral bioavailability of the drug in humans. RESULTS: A total of 21 patients were enrolled. Twenty treated patients received a total of 39 cycles of treatment. The most common treatment-related adverse events occurring with greater than 20% incidence were fatigue (25%) and nausea (20%). Following intravenous administration, plasma concentrations declined in a biphasic manner, resulting in mean terminal half-lives between 5 and 10 hours. The mean Cmax and AUC0-inf increased nearly linearly with dose, ranging from 0.067 to 0.287 microg/ml and 0.103 to 0.553 microg h/ml, respectively. The CL and Vss remained unchanged with increasing dose levels, averaging 38 l/h/m2 and 212 l/m2, respectively. Average oral bioavailability was 19% (range: 4-33%). Three (15%) patients experienced a best response of stable disease. Study enrollment was terminated during dose-escalation due to a change in the development strategy for the study drug. CONCLUSIONS: SNS-032 administered as a weekly 1-h infusion was well tolerated, although study enrollment was terminated during dose-escalation and the MTD of SNS-032 administered intravenously on days 1, 8, and 15 of each treatment cycle was not reached. Tumor progression or stable disease was determined to be the best response in all evaluable patients. At the dose levels tested, the oral bioavailability of SNS-032 ranged from 4-33%. The data suggest that oral administration of SNS-032 may be feasible, though the tolerability and bioavailability of the oral formulation would have to be formally assessed.
38 schema:genre research_article
39 schema:inLanguage en
40 schema:isAccessibleForFree false
41 schema:isPartOf N0ec47ca154b04ca7953b078ad95527ca
42 Ne0f69c5d369a4b3392c8b89ba2c56f55
43 sg:journal.1094201
44 schema:name A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors
45 schema:pagination 59-65
46 schema:productId N105ea69dd6b7475d962eaa66533a2e2f
47 N941cf0a366c64c22ac8e8b96c7288e4a
48 Nc570ea0243ad43219f8a6e3d9347d76f
49 Ncd72d3edaaed4d71a1e24f4d61157676
50 Nfd8077202c44419fa9df85fdd2ce3df1
51 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044972352
52 https://doi.org/10.1007/s10637-007-9090-3
53 schema:sdDatePublished 2019-04-15T09:22
54 schema:sdLicense https://scigraph.springernature.com/explorer/license/
55 schema:sdPublisher N031d60777a214dde9c434aa1e15f5a4a
56 schema:url http://link.springer.com/10.1007%2Fs10637-007-9090-3
57 sgo:license sg:explorer/license/
58 sgo:sdDataset articles
59 rdf:type schema:ScholarlyArticle
60 N02bad94f4fe7491b906d022c5d69a278 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Infusions, Intravenous
62 rdf:type schema:DefinedTerm
63 N031d60777a214dde9c434aa1e15f5a4a schema:name Springer Nature - SN SciGraph project
64 rdf:type schema:Organization
65 N0ea725702b8c4ac3868d138236bf48a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Neoplasm Metastasis
67 rdf:type schema:DefinedTerm
68 N0ec2807d1f334ade92632765f21ac32c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Area Under Curve
70 rdf:type schema:DefinedTerm
71 N0ec47ca154b04ca7953b078ad95527ca schema:issueNumber 1
72 rdf:type schema:PublicationIssue
73 N105ea69dd6b7475d962eaa66533a2e2f schema:name dimensions_id
74 schema:value pub.1044972352
75 rdf:type schema:PropertyValue
76 N1b95010bb44a4a71b8c0645778a143cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Time Factors
78 rdf:type schema:DefinedTerm
79 N1c70daddf2d842cca11c6508c13fc8a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Middle Aged
81 rdf:type schema:DefinedTerm
82 N1c88754fcd1444e4b9b3649333e89ac3 schema:name Methylgene, Montreal, Quebec, Canada
83 rdf:type schema:Organization
84 N2664953072224c38aa4e8cf61b90b6e5 rdf:first sg:person.012616064757.23
85 rdf:rest rdf:nil
86 N2f89d00122b14f509086141c2d577082 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Neutropenia
88 rdf:type schema:DefinedTerm
89 N3351f268906d4ad2aa73b9f0e0515405 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Oxazoles
91 rdf:type schema:DefinedTerm
92 N39ab6acb42cf495fbc843596c77a0f75 rdf:first sg:person.0774753133.57
93 rdf:rest N450c82b9f7294f2d82e858ad07fe0c93
94 N3d71d4b901194899881bb02d95b2c842 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Thiazoles
96 rdf:type schema:DefinedTerm
97 N419874bf8218447aab5a0cec4f3c08af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Aged
99 rdf:type schema:DefinedTerm
100 N450c82b9f7294f2d82e858ad07fe0c93 rdf:first sg:person.01074762666.14
101 rdf:rest Ne9da0402cefc4208823cf39321b7c1f9
102 N49b3e507bc804c2faf5e22715f5adaea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Radiotherapy, Adjuvant
104 rdf:type schema:DefinedTerm
105 N4e893f104b6f460ba9a9dbc3ecbd2c43 rdf:first sg:person.01136603555.42
106 rdf:rest N39ab6acb42cf495fbc843596c77a0f75
107 N57b760e501754084b3c7a095bb9bddfd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Male
109 rdf:type schema:DefinedTerm
110 N5f3c9ea2d0344f1f94b33678795d8cec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Neoplasms
112 rdf:type schema:DefinedTerm
113 N74b3e57b51464276b65d92d66f17a45c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Anemia
115 rdf:type schema:DefinedTerm
116 N90810ff547df41fb88c596b770f648e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Administration, Oral
118 rdf:type schema:DefinedTerm
119 N92d53c7ab5b746978e36cfb37777136d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Adult
121 rdf:type schema:DefinedTerm
122 N941cf0a366c64c22ac8e8b96c7288e4a schema:name pubmed_id
123 schema:value 17938863
124 rdf:type schema:PropertyValue
125 Nb06223a438e2448fbb764e855c5e9863 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Humans
127 rdf:type schema:DefinedTerm
128 Nb3da32ccb88443dd8561b02ef2100f4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Treatment Outcome
130 rdf:type schema:DefinedTerm
131 Nc570ea0243ad43219f8a6e3d9347d76f schema:name readcube_id
132 schema:value d637d843eccfb41457e43f3ed20db3cf1787635efd177aec3da212ece461fcba
133 rdf:type schema:PropertyValue
134 Ncd72d3edaaed4d71a1e24f4d61157676 schema:name doi
135 schema:value 10.1007/s10637-007-9090-3
136 rdf:type schema:PropertyValue
137 Nce44ac8ae4a7424b9bcb171fa8ed4d55 schema:affiliation https://www.grid.ac/institutes/grid.422684.e
138 schema:familyName Adelman
139 schema:givenName Daniel C.
140 rdf:type schema:Person
141 Nd3c16dc0b36147ae858536c04d9cbf34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Biological Availability
143 rdf:type schema:DefinedTerm
144 Ne03f090571564f28bc5b4c1f55edb85f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Angiogenesis Inhibitors
146 rdf:type schema:DefinedTerm
147 Ne0f69c5d369a4b3392c8b89ba2c56f55 schema:volumeNumber 26
148 rdf:type schema:PublicationVolume
149 Ne9da0402cefc4208823cf39321b7c1f9 rdf:first Nce44ac8ae4a7424b9bcb171fa8ed4d55
150 rdf:rest N2664953072224c38aa4e8cf61b90b6e5
151 Ne9e73d17ced04cabb35fed464c3ee922 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Dose-Response Relationship, Drug
153 rdf:type schema:DefinedTerm
154 Nf04d338c07994a7aa64a5091a3989395 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Female
156 rdf:type schema:DefinedTerm
157 Nf8f7fb383042459f90d837515491c191 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name CDC2-CDC28 Kinases
159 rdf:type schema:DefinedTerm
160 Nfa903ddde57b4203b2198d1abaf95cbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Half-Life
162 rdf:type schema:DefinedTerm
163 Nfd8077202c44419fa9df85fdd2ce3df1 schema:name nlm_unique_id
164 schema:value 8309330
165 rdf:type schema:PropertyValue
166 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
167 schema:name Medical and Health Sciences
168 rdf:type schema:DefinedTerm
169 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
170 schema:name Pharmacology and Pharmaceutical Sciences
171 rdf:type schema:DefinedTerm
172 sg:journal.1094201 schema:issn 0167-6997
173 1573-0646
174 schema:name Investigational New Drugs
175 rdf:type schema:Periodical
176 sg:person.01074762666.14 schema:affiliation N1c88754fcd1444e4b9b3649333e89ac3
177 schema:familyName Martell
178 schema:givenName Robert E.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074762666.14
180 rdf:type schema:Person
181 sg:person.01136603555.42 schema:affiliation https://www.grid.ac/institutes/grid.254444.7
182 schema:familyName Heath
183 schema:givenName Elisabeth I.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136603555.42
185 rdf:type schema:Person
186 sg:person.012616064757.23 schema:affiliation https://www.grid.ac/institutes/grid.254444.7
187 schema:familyName LoRusso
188 schema:givenName Patricia M.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012616064757.23
190 rdf:type schema:Person
191 sg:person.0774753133.57 schema:affiliation https://www.grid.ac/institutes/grid.66875.3a
192 schema:familyName Bible
193 schema:givenName Keith
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774753133.57
195 rdf:type schema:Person
196 sg:pub.10.1023/b:drug.0000026258.02846.1c schema:sameAs https://app.dimensions.ai/details/publication/pub.1012390955
197 https://doi.org/10.1023/b:drug.0000026258.02846.1c
198 rdf:type schema:CreativeWork
199 https://app.dimensions.ai/details/publication/pub.1074769896 schema:CreativeWork
200 https://doi.org/10.1016/j.semcancer.2005.04.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032104046
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/j.ygyno.2005.05.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046291497
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/s0002-9440(10)65593-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036900656
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1158/1078-0432.ccr-03-0050 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037461456
209 rdf:type schema:CreativeWork
210 https://doi.org/10.2741/1871 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070914153
211 rdf:type schema:CreativeWork
212 https://www.grid.ac/institutes/grid.254444.7 schema:alternateName Wayne State University
213 schema:name Wayne State University/Karmanos Cancer Institute, 4100 John R, 4HWCRC, 48201, Detroit, MI, USA
214 rdf:type schema:Organization
215 https://www.grid.ac/institutes/grid.422684.e schema:alternateName Sunesis (United States)
216 schema:name Sunesis Pharmaceuticals, Inc., San Francisco, CA, USA
217 rdf:type schema:Organization
218 https://www.grid.ac/institutes/grid.66875.3a schema:alternateName Mayo Clinic
219 schema:name Mayo Clinic, Rochester, MN, USA
220 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...